Literature summary for 3.4.14.5 extracted from

Bergman, A.; Mistry, G.C.; Luo, W.L.; Liu, Q.; Stone, J.; Wang, A.; Zeng, W.; Chen, L.; Dilzer, S.; Lasseter, K.; Herman, G.A.; Wagner, J.A.; Krishna, R.
Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers (2007), Biopharm. Drug Dispos., 28, 307-313.

Search for more literature for 3.4.14.5

Inhibitors

Inhibitors	Comment	Organism	Structure
sitagliptin	highly selective orally active dipeptidyl peptidase-4 inhibitor recently approved in the United States for the treatment of type 2 diabetes. Plasma AUC0_1 (area under the plasma concentration-time curve) increases in a dose-proportional manner over the 25-400 mg dose range	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)